314 related articles for article (PubMed ID: 16185681)
21. Applying quantitative methods for detecting new drug safety signals in pharmacovigilance national database.
Shalviri G; Mohammad K; Majdzadeh R; Gholami K
Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1136-40. PubMed ID: 17705214
[TBL] [Abstract][Full Text] [Related]
22. Factors influencing the spontaneous reporting of adverse drug reactions--the experience of the Slovak Republic.
Tisonová J; Szalayová A; Kriska M; Gibala P; Foltán V
Pharmacoepidemiol Drug Saf; 2004 May; 13(5):333-7. PubMed ID: 15133786
[TBL] [Abstract][Full Text] [Related]
23. Adverse drug reactions in patients older than 70 years during the heat wave occurred in France in summer 2003: A study from the French PharmacoVigilance Database.
Michenot F; Sommet A; Bagheri H; Lapeyre-Mestre M; Montastruc JL;
Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):735-40. PubMed ID: 16924603
[TBL] [Abstract][Full Text] [Related]
24. Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions.
Bousquet C; Lagier G; Lillo-Le Louët A; Le Beller C; Venot A; Jaulent MC
Drug Saf; 2005; 28(1):19-34. PubMed ID: 15649103
[TBL] [Abstract][Full Text] [Related]
25. Signal detection in pharmacovigilance: empirical evaluation of data mining tools.
Chan KA; Hauben M
Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):597-9. PubMed ID: 16134080
[No Abstract] [Full Text] [Related]
26. A comparative study of adverse drug reactions during two heat waves that occurred in France in 2003 and 2006.
Sommet A; Durrieu G; Lapeyre-Mestre M; Montastruc JL;
Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):285-8. PubMed ID: 22162094
[TBL] [Abstract][Full Text] [Related]
27. New terminology services based on term comparison using semantic definitions and similarity computation.
Bousquet C; Jaulent MC; Le Bozec C; Degoulet P
Stud Health Technol Inform; 2003; 95():385-90. PubMed ID: 14664017
[TBL] [Abstract][Full Text] [Related]
28. Adverse drug reaction reporting by nurses: analysis of Italian pharmacovigilance database.
Conforti A; Opri S; D'Incau P; Sottosanti L; Moretti U; Ferrazin F; Leone R
Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):597-602. PubMed ID: 22337264
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of an ontological resource for pharmacovigilance.
Jaulent MC; Alecu I
Stud Health Technol Inform; 2009; 150():522-6. PubMed ID: 19745366
[TBL] [Abstract][Full Text] [Related]
30. [Adverse drug reactions definitions and terminology].
Rabinovitz H; Berkowitch M; Golik A; Shani S
Harefuah; 2001 Dec; 140(12):1181-6, 1228. PubMed ID: 11789305
[TBL] [Abstract][Full Text] [Related]
31. Semantic categories and relations for modelling adverse drug reactions towards a categorial structure for pharmacovigilance.
Bousquet C; Trombert B; Kumar A; Rodrigues JM
AMIA Annu Symp Proc; 2008 Nov; 2008():61-5. PubMed ID: 18998982
[TBL] [Abstract][Full Text] [Related]
32. [Pharmacovigilance seen by a selected group of general practitioners and of residents in the Midi-Pyrénées region].
Pouget-Zago P; Lapeyre-Mestre M; Bagheri H; Montastruc JL
Therapie; 1995; 50(5):459-62. PubMed ID: 8571286
[TBL] [Abstract][Full Text] [Related]
33. A potential competition bias in the detection of safety signals from spontaneous reporting databases.
Pariente A; Didailler M; Avillach P; Miremont-Salamé G; Fourrier-Reglat A; Haramburu F; Moore N
Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1166-71. PubMed ID: 20848561
[TBL] [Abstract][Full Text] [Related]
34. Points of view on adverse drug reactions terminology.
Benichou C; Castle W
Therapie; 1998; 53(2):145-9. PubMed ID: 9773114
[TBL] [Abstract][Full Text] [Related]
35. Experience using MedDRA for global events coding in HIV clinical trials.
Tonéatti C; Saïdi Y; Meiffrédy V; Tangre P; Harel M; Eliette V; Dormont J; Pierre Aboulker J
Contemp Clin Trials; 2006 Feb; 27(1):13-22. PubMed ID: 16288902
[TBL] [Abstract][Full Text] [Related]
36. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?
Trifirò G; Pariente A; Coloma PM; Kors JA; Polimeni G; Miremont-Salamé G; Catania MA; Salvo F; David A; Moore N; Caputi AP; Sturkenboom M; Molokhia M; Hippisley-Cox J; Acedo CD; van der Lei J; Fourrier-Reglat A;
Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1176-84. PubMed ID: 19757412
[TBL] [Abstract][Full Text] [Related]
37. From narrative descriptions to MedDRA: automagically encoding adverse drug reactions.
Combi C; Zorzi M; Pozzani G; Moretti U; Arzenton E
J Biomed Inform; 2018 Aug; 84():184-199. PubMed ID: 29981491
[TBL] [Abstract][Full Text] [Related]
38. Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs.
Bate A; Lindquist M; Orre R; Edwards IR; Meyboom RH
Eur J Clin Pharmacol; 2002 Oct; 58(7):483-90. PubMed ID: 12389072
[TBL] [Abstract][Full Text] [Related]
39. The EU-ADR Web Platform: delivering advanced pharmacovigilance tools.
Oliveira JL; Lopes P; Nunes T; Campos D; Boyer S; Ahlberg E; van Mulligen EM; Kors JA; Singh B; Furlong LI; Sanz F; Bauer-Mehren A; Carrascosa MC; Mestres J; Avillach P; Diallo G; Díaz Acedo C; van der Lei J
Pharmacoepidemiol Drug Saf; 2013 May; 22(5):459-67. PubMed ID: 23208789
[TBL] [Abstract][Full Text] [Related]
40. The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case-control study.
van Hunsel F; Talsma A; van Puijenbroek E; de Jong-van den Berg L; van Grootheest K
Pharmacoepidemiol Drug Saf; 2011 Mar; 20(3):286-91. PubMed ID: 21351310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
